ROS-responsive drug-releasing injectable microgels for ameliorating myocardial infarction

Shuqin Wang,Yuejun Yao,Liang Song,Zihe Zhai,Shifen Li,Zhaolong Wang,Liyin Shen,Yang Zhu,Wenxing Liu,Changyou Gao
DOI: https://doi.org/10.1016/j.biomaterials.2024.122534
IF: 14
2024-03-19
Biomaterials
Abstract:Despite of the recent advances in regulatory T cell (Treg) therapy, a limited number of available cells and specificity at the desired tissue site have severely compromised their efficacy. Herein, an injectable drug-releasing (MTK-TK-drug) microgel system in response to in situ stimulation by reactive oxygen species (ROS) was constructed with a coaxial capillary microfluidic system and UV curing. The spherical microgels with a size of 150 μm were obtained. The MTK-TK-drug microgels efficiently converted the pro-inflammatory Th17 cells into anti-inflammatory regulatory T cells (Treg) cells in vitro , and the ROS-scavenging materials synergistically enhanced the effect by modulating the inflammation microenvironment. Thus, the microgels significantly reduced cardiomyocyte apoptosis and decreased the inflammatory response in the early stages of post-myocardial infarction (MI) in vivo , thereby reducing fibrosis, promoting vascularization, and preserving cardiac function. Overall, our results indicate that the MTK-TK-drug microgels can attenuate the inflammatory response and improve MI therapeutic effects in vivo .
engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?